Childhood cancers trials in Israel

In Israel 44 Also abroad 2459

44 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Ramat Gan, Tel Aviv
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Haifa, Jerusalem, Ramat Gan, Tel Aviv
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
Phase 1/2Taking people
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Where
Haifa, Jerusalem, Ramat Gan, Tel Aviv
Age
2 years and over
People
420 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Beersheba, Jerusalem, Tel Aviv, Tel-Hashomer
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Haifa, Ramat Gan
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1/2Taking people
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Where
Haifa, Petah Tikva, Ramat Gan
Age
1 month to 17 years
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00
No phaseTaking people
Met Non Small Cell Cancer Registry (MOMENT)
Where
Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
People
700 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Tel Aviv
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Petah Tikva
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 1/2Taking people
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Where
Ramat Gan
Age
1 year to 30 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07387926
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Beersheba, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 1/2Taking people
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Where
Haifa, Ramat Gan
Age
1 month to 17 years
People
50 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Where
Jerusalem, Tel Aviv
People
64 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07602777
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Haifa, Petah Tikva, Ramat Gan, Tel Aviv
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 2Enrolling by invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Where
Tel Aviv
People
1,500 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT05041309 · EU 2023-507041-28-00
Phase 2Taking people
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Where
Jerusalem
Age
12 months to 21 years
People
10
Run by
Shaare Zedek Medical Center
See details and how to joinNCT07537400
No phaseTaking people
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
Where
Jerusalem
Age
Up to 17 years
People
1,600 worldwide
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT06651580
Phase 2/3Taking people
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Where
Haifa, Petah Tikva, Tel Aviv
Age
1 month to 18 years
People
1,800 worldwide
Run by
St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00
Phase 2Taking people
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Where
Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
12 years and over
People
100 worldwide
Run by
AbbVie
See details and how to joinNCT07196644 · EU 2024-518871-74-00
No phaseTaking people
International Rare Brain Tumor Registry
Where
Haifa, Petah Tikva, Tel Aviv, Tel HaShomer
Age
Up to 45 years
People
5,800 worldwide
Run by
Children's National Research Institute
See details and how to joinNCT05697874
Phase 1/2Taking people
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Where
Hod HaSharon
Age
6 months to 17 years
People
370 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00
Phase 2Taking people
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Where
Jerusalem, Tel HaShomer
Age
2 years to 39 years
People
360 worldwide
Run by
University of California, San Francisco
See details and how to joinNCT05009992 · EU 2023-507598-16-00
Phase 3Taking people
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Where
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
Up to 18 years
People
683 worldwide
Run by
University Hospital Muenster
See details and how to joinNCT04043494 · EU 2023-508101-24-00